Skip to main content
SpringerLink
Log in

Pathophysiology of Schizophrenia

  • Chapter
  • First Online:
Schizophrenia

  • 4944 Accesses

Abstract

Over the past two decades, significant advances have been made in understanding the pathophysiology of schizophrenia. Despite the questionable validity of schizophrenia as a unitary diagnostic construct, consistent neurobiological features of this disorder are identified. Much of this knowledge, however, has yet to make a substantial impact on clinical practice. Data from neuroimaging, electrophysiology, and neuropathology are now being integrated in ways which may ultimately generate clinically relevant applications. This chapter summarizes our current knowledge about the pathophysiology of schizophrenia from several perspectives and discusses clinically relevant developments and future directions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kraepelin E. Dementia Praecox and Paraphrenia, 1919. Robertson G, editor. New York: RE Krieger; 1971.

    Google Scholar 

  2. Plum F. Prospects for research on schizophrenia. 3. Neurophysiology. Neuropathological findings. Neurosci Res Program Bull. 1972;10(4):384–8.

    CAS  PubMed  Google Scholar 

  3. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2(7992):924–6.

    CAS  PubMed  Google Scholar 

  4. Weinberger DR. From neuropathology to neurodevelopment. Lancet. 1995;346(8974):552–7.

    CAS  PubMed  Google Scholar 

  5. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry. 1998;172:110–20.

    CAS  PubMed  Google Scholar 

  6. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157(1):16–25.

    CAS  PubMed  Google Scholar 

  7. Shepherd AM, Laurens KR, Matheson SL, Carr VJ, Green MJ. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev. 2012;36(4):1342–56.

    PubMed  Google Scholar 

  8. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry. 2005;162(12):2233–45.

    PubMed  Google Scholar 

  9. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry. 2006;188:510–8.

    PubMed  Google Scholar 

  10. Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Trans Psychiatry. 2012;2:e190.

    CAS  Google Scholar 

  11. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet. 1994;344(8934):1434.

    CAS  PubMed  Google Scholar 

  12. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Rimol LM, Hartberg CB, Nesvåg R, Fennema-Notestine C, Hagler DJ, Pung CJ, et al. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol Psychiatry. 2010;68(1):41–50.

    PubMed  Google Scholar 

  14. Rimol LM, Nesvåg R, Hagler DJ, Bergmann O, Fennema-Notestine C, Hartberg CB, et al. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. Biol Psychiatry. 2012;71(6):552–60.

    PubMed  Google Scholar 

  15. Shapleske J, Rossell SL, Woodruff PW, David AS. The planum temporale: a systematic, quantitative review of its structural, functional and clinical significance. Brain Res Brain Res Rev. 1999;29(1):26–49.

    CAS  PubMed  Google Scholar 

  16. Sun J, Maller JJ, Guo L, Fitzgerald PB. Superior temporal gyrus volume change in schizophrenia: a review on region of interest volumetric studies. Brain Res Rev. 2009;61(1):14–32. Research Support, Non-U.S. Gov’t Review.

    PubMed  Google Scholar 

  17. Brambilla P, Perlini C, Rajagopalan P, Saharan P, Rambaldelli G, Bellani M, et al. Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study. Br J Psychiatry. 2013;202(1):50–5.

    CAS  PubMed  Google Scholar 

  18. Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res. 2004;70(2–3):117–45.

    PubMed  Google Scholar 

  19. Palaniyappan L, Balain V, Liddle PF. The neuroanatomy of psychotic diathesis: a meta-analytic review. J Psychiatr Res. 2012;46(10):1249–56.

    PubMed  Google Scholar 

  20. Borgwardt SJ, Riecher-Rössler A, Dazzan P, Chitnis X, Aston J, Drewe M, et al. Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry. 2007;61(10):1148–56.

    PubMed  Google Scholar 

  21. Mechelli A, Riecher-Rössler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry. 2011;68(5):489–95.

    PubMed  Google Scholar 

  22. Seidman LJ, Pantelis C, Keshavan MS, Faraone SV, Goldstein JM, Horton NJ, et al. A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull. 2003;29(4):803–30.

    PubMed  Google Scholar 

  23. Boos HB, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry. 2007;64(3):297–304.

    PubMed  Google Scholar 

  24. Yao L, Lui S, Liao Y, Du MY, Hu N, Thomas JA, et al. White matter deficits in first episode schizophrenia: an activation likelihood estimation meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45C:100–6.

    Google Scholar 

  25. Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res. 2009;108(1–3):3–10.

    PubMed  Google Scholar 

  26. Gur RE, Gur RC. Functional magnetic resonance imaging in schizophrenia. Dialogues Clin Neurosci. 2010;12(3):333–43.

    PubMed  PubMed Central  Google Scholar 

  27. Berman KF, Meyer-Lindenberg A. Functional brain imaging studies in schizophrenia. In: Charney D, Nestler E, editors. Neurobiology of mental illness. 2nd ed. Oxford, MA: Oxford University Press; 2004.

    Google Scholar 

  28. Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A, Caverzasi E, et al. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2007;31(4):465–84.

    PubMed  Google Scholar 

  29. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66(8):811–22.

    PubMed  PubMed Central  Google Scholar 

  30. Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, et al. Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry. 2007;64(12):1356–66.

    PubMed  Google Scholar 

  31. Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry. 2011;168(1):73–81.

    PubMed  Google Scholar 

  32. Whitfield-Gabrieli S, Ford JM. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol. 2012;8:49–76.

    PubMed  Google Scholar 

  33. Jezzard P, Buxton RB. The clinical potential of functional magnetic resonance imaging. J Magn Reson Imaging. 2006;23(6):787–93.

    PubMed  Google Scholar 

  34. Roth WT, Cannon EH. Some features of the auditory evoked response in schizophrenics. Arch Gen Psychiatry. 1972;27(4):466–71.

    CAS  PubMed  Google Scholar 

  35. Linden DE. The p300: where in the brain is it produced and what does it tell us? Neuroscientist. 2005;11(6):563–76.

    CAS  PubMed  Google Scholar 

  36. Ford JM. Schizophrenia: the broken P300 and beyond. Psychophysiology. 1999;36(6):667–82.

    CAS  PubMed  Google Scholar 

  37. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004;70(2–3):315–29.

    PubMed  Google Scholar 

  38. Winterer G, Egan MF, Raedler T, Sanchez C, Jones DW, Coppola R, et al. P300 and genetic risk for schizophrenia. Arch Gen Psychiatry. 2003;60(11):1158–67.

    PubMed  Google Scholar 

  39. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156(2–3):234–58.

    CAS  Google Scholar 

  40. Perry W, Geyer MA, Braff DL. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry. 1999;56(3):277–81.

    CAS  PubMed  Google Scholar 

  41. Weike AI, Bauer U, Hamm AO. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiatry. 2000;47(1):61–70.

    CAS  PubMed  Google Scholar 

  42. Hasenkamp W, Epstein MP, Green A, Wilcox L, Boshoven W, Lewison B, et al. Heritability of acoustic startle magnitude, prepulse inhibition, and startle latency in schizophrenia and control families. Psychiatry Res. 2010;178(2):236–43.

    PubMed  PubMed Central  Google Scholar 

  43. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry. 2000;157(10):1660–8.

    CAS  PubMed  Google Scholar 

  44. Hammer TB, Oranje B, Skimminge A, Aggernæs B, Ebdrup BH, Glenthøj B, et al. Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia. J Psychiatry Neurosci. 2013;38(1):34–42.

    PubMed  PubMed Central  Google Scholar 

  45. Griffith J, Hoffer LD, Adler LE, Zerbe GO, Freedman R. Effects of sound intensity on a midlatency evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Psychophysiology. 1995;32(5):460–6.

    CAS  PubMed  Google Scholar 

  46. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 1982;17(6):639–54.

    CAS  PubMed  Google Scholar 

  47. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150(12):1856–61.

    CAS  PubMed  Google Scholar 

  48. Waldo MC, Cawthra E, Adler LE, Dubester S, Staunton M, Nagamoto H, et al. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophr Res. 1994;12(2):93–106.

    CAS  PubMed  Google Scholar 

  49. Hall MH, Schulze K, Rijsdijk F, Picchioni M, Ettinger U, Bramon E, et al. Heritability and reliability of P300, P50 and duration mismatch negativity. Behav Genet. 2006;36(6):845–57.

    PubMed  Google Scholar 

  50. Clementz BA, Geyer MA, Braff DL. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry. 1998;155(12):1691–4.

    CAS  PubMed  Google Scholar 

  51. Becker J, Gomes I, Ghisolfi ES, Schuch A, Ramos FL, Ehlers JA, et al. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin Neurophysiol. 2004;115(2):396–401.

    CAS  PubMed  Google Scholar 

  52. Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull. 2008;34(4):760–73.

    PubMed  PubMed Central  Google Scholar 

  53. Alho K, Woods DL, Algazi A, Knight RT, Näätänen R. Lesions of frontal cortex diminish the auditory mismatch negativity. Electroencephalogr Clin Neurophysiol. 1994;91(5):353–62.

    CAS  PubMed  Google Scholar 

  54. Umbricht D, Koller R, Schmid L, Skrabo A, Grübel C, Huber T, et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry. 2003;53(12):1120–31.

    PubMed  Google Scholar 

  55. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005;62(2):127–36.

    PubMed  Google Scholar 

  56. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11(2):100–13.

    CAS  PubMed  Google Scholar 

  57. Linkenkaer-Hansen K, Smit DJ, Barkil A, van Beijsterveldt TE, Brussaard AB, Boomsma DI, et al. Genetic contributions to long-range temporal correlations in ongoing oscillations. J Neurosci. 2007;27(50):13882–9.

    CAS  PubMed  Google Scholar 

  58. Kwon JS, O’Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG, et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry. 1999;56(11):1001–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci U S A. 2006;103(52):19878–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Spencer KM, Niznikiewicz MA, Nestor PG, Shenton ME, McCarley RW. Left auditory cortex gamma synchronization and auditory hallucination symptoms in schizophrenia. BMC Neurosci. 2009;10:85.

    PubMed  PubMed Central  Google Scholar 

  61. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007;33(1):69–94.

    PubMed  PubMed Central  Google Scholar 

  62. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74(6):400–9.

    CAS  PubMed  Google Scholar 

  63. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12(10):3721–8.

    CAS  PubMed  Google Scholar 

  64. Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Chen Y, Dalton TP, et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci. 2010;30(7):2547–58.

    CAS  PubMed  Google Scholar 

  65. O’Donnell P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur J Neurosci. 2012;35(12):1866–70.

    PubMed  Google Scholar 

  66. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetyl cysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34(3):167–77.

    CAS  PubMed  Google Scholar 

  67. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry. 1988;45(2):189–92.

    CAS  PubMed  Google Scholar 

  68. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71.

    CAS  PubMed  Google Scholar 

  69. Tanaka S, Matsunaga H, Kimura M, Tatsumi K, Hidaka Y, Takano T, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003;141(1–2):155–64.

    CAS  PubMed  Google Scholar 

  70. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638–46.

    PubMed  PubMed Central  Google Scholar 

  71. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):520–7.

    CAS  PubMed  Google Scholar 

  72. Albus M, Ackenheil M, Engel RR, Müller F. Situational reactivity of autonomic functions in schizophrenic patients. Psychiatry Res. 1982;6(3):361–70.

    CAS  PubMed  Google Scholar 

  73. Brenner K, Liu A, Laplante DP, Lupien S, Pruessner JC, Ciampi A, et al. Cortisol response to a psychosocial stressor in schizophrenia: blunted, delayed, or normal? Psychoneuroendocrinology. 2009;34(6):859–68.

    CAS  PubMed  Google Scholar 

  74. Yeragani VK. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can J Psychiatry. 1990;35(2):128–32.

    CAS  PubMed  Google Scholar 

  75. Goldman MB, Blake L, Marks RC, Hedeker D, Luchins DJ. Association of nonsuppression of cortisol on the DST with primary polydipsia in chronic schizophrenia. Am J Psychiatry. 1993;150(4):653–5.

    CAS  PubMed  Google Scholar 

  76. Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D, et al. Neurometabolites in schizophrenia and bipolar disorder—a systematic review and meta-analysis. Psychiatry Res. 2012;203(2–3):111–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia—a systematic review and meta-analysis. Biol Psychiatry. 2011;69(5):495–503.

    PubMed  Google Scholar 

  78. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013;39(1):120–9.

    PubMed  PubMed Central  Google Scholar 

  79. Dager SR, Corrigan NM, Richards TL, Posse S. Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn Reson Imaging. 2008;19(2):81–96.

    PubMed  PubMed Central  Google Scholar 

  80. Smesny S, Rosburg T, Nenadic I, Fenk KP, Kunstmann S, Rzanny R, et al. Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage. 2007;35(2):729–37.

    PubMed  Google Scholar 

  81. Silverman DH. Brain 18 F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45(4):594–607.

    PubMed  Google Scholar 

  82. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull. 2013;39(1):33–42.

    PubMed  PubMed Central  Google Scholar 

  83. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5(3):267–71.

    CAS  PubMed  Google Scholar 

  85. Gallinat J, Heinz A. Combination of multimodal imaging and molecular genetic information to investigate complex psychiatric disorders. Pharmacopsychiatry. 2006;39 Suppl 1:S76–9.

    PubMed  Google Scholar 

  86. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44(7):660–9.

    CAS  PubMed  Google Scholar 

  87. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 1980;286(5768):74–6.

    CAS  PubMed  Google Scholar 

  88. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995;52(4):258–66.

    CAS  PubMed  Google Scholar 

  89. Piper M, Beneyto M, Burne TH, Eyles DW, Lewis DA, McGrath JJ. The neurodevelopmental hypothesis of schizophrenia: convergent clues from epidemiology and neuropathology. Psychiatr Clin North Am. 2012;35(3):571–84.

    PubMed  Google Scholar 

  90. Stan AD, Lewis DA. Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies. Curr Pharm Biotechnol. 2012;13(8):1557–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Vreugdenhil M, Jefferys JG, Celio MR, Schwaller B. Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. J Neurophysiol. 2003;89(3):1414–22.

    PubMed  Google Scholar 

  92. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–8.

    CAS  PubMed  Google Scholar 

  94. Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC. Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A. 1996;93(21):11962–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Harrison PJ, Law AJ, Eastwood SL. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann N Y Acad Sci. 2003;1003:94–101.

    CAS  PubMed  Google Scholar 

  96. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90–107.

    CAS  PubMed  Google Scholar 

  97. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122(Pt 4):593–624.

    PubMed  Google Scholar 

  98. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57(1):65–73.

    CAS  PubMed  Google Scholar 

  99. Höistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JD, Hof PR. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front Neuroanat. 2009;3:9.

    PubMed  PubMed Central  Google Scholar 

  100. Kovalenko S, Bergmann A, Schneider-Axmann T, Ovary I, Majtenyi K, Havas L, et al. Regio entorhinalis in schizophrenia: more evidence for migrational disturbances and suggestions for a new biological hypothesis. Pharmacopsychiatry. 2003;36 Suppl 3:S158–61.

    PubMed  Google Scholar 

  101. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R. Dysfunctional neural plasticity in patients with schizophrenia. Arch Gen Psychiatry. 2008;65(4):378–85.

    PubMed  Google Scholar 

  102. Mears RP, Spencer KM. Electrophysiological assessment of auditory stimulus-specific plasticity in schizophrenia. Biol Psychiatry. 2012;71(6):503–11.

    PubMed  PubMed Central  Google Scholar 

  103. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 2005;25(2):372–83.

    CAS  PubMed  Google Scholar 

  104. Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res. 2012;46(1):1–11.

    PubMed  Google Scholar 

  105. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry. 2009;66(6):549–53.

    CAS  PubMed  Google Scholar 

  106. Erlenmeyer-Kimling L. Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness. Am J Med Genet. 2000;97(1):65–71.

    CAS  PubMed  Google Scholar 

  107. Xu T, Chan RC, Compton MT. Minor physical anomalies in patients with schizophrenia, unaffected first-degree relatives, and healthy controls: a meta-analysis. PLoS One. 2011;6(9):e24129.

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Walker EF, Savoie T, Davis D. Neuromotor precursors of schizophrenia. Schizophr Bull. 1994;20(3):441–51.

    CAS  PubMed  Google Scholar 

  109. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57 Suppl 9:5–9.

    PubMed  Google Scholar 

  110. Voineskos D, Rogasch NC, Rajji TK, Fitzgerald PB, Daskalakis ZJ. A review of evidence linking disrupted neural plasticity to schizophrenia. Can J Psychiatry. 2013;58(2):86–92.

    PubMed  Google Scholar 

  111. Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res. 1999;33(6):513–21.

    CAS  PubMed  Google Scholar 

  112. Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect. 1993;91(2–3):111–34.

    CAS  PubMed  Google Scholar 

  113. Keshavan MS, Morris DW, Sweeney JA, Pearlson G, Thaker G, Seidman LJ, et al. A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: the schizo-bipolar scale. Schizophr Res. 2011;133(1–3):250–4.

    PubMed  PubMed Central  Google Scholar 

  114. Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the bipolar and schizophrenia network on intermediate phenotypes (B-SNIP) study. Am J Psychiatry. 2013;170(11):1275–84.

    PubMed  Google Scholar 

  115. Ivleva EI, Morris DW, Moates AF, Suppes T, Thaker GK, Tamminga CA. Genetics and intermediate phenotypes of the schizophrenia—bipolar disorder boundary. Neurosci Biobehav Rev. 2010;34(6):897–921.

    CAS  PubMed  Google Scholar 

  116. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748–52.

    CAS  PubMed  Google Scholar 

  117. Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI, et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381(9875):1371–9.

    CAS  Google Scholar 

  118. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–93.

    CAS  PubMed  Google Scholar 

  119. Keshavan MS. DSM-5 and incremental progress in psychiatric nosology. Asian J Psychiatr. 2013;6(2):97–8.

    PubMed  Google Scholar 

  120. Cuthbert B, Insel T. The data of diagnosis: new approaches to psychiatric classification. Psychiatry. 2010;73(4):311–4.

    PubMed  Google Scholar 

  121. Keshavan MS, Clementz BA, Pearlson GD, Sweeney JA, Tamminga CA. Reimagining psychoses: an agnostic approach to diagnosis. Schizophr Res. 2013;146(1–3):10–6.

    PubMed  Google Scholar 

  122. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry. 2008;7(1):22–8.

    PubMed  PubMed Central  Google Scholar 

  123. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17(12):1174–9.

    CAS  PubMed  Google Scholar 

  124. Borgwardt S, Fusar-Poli P. Third-generation neuroimaging in early schizophrenia: translating research evidence into clinical utility. Br J Psychiatry. 2012;200(4):270–2.

    PubMed  Google Scholar 

  125. Vaccarino FM, Stevens HE, Kocabas A, Palejev D, Szekely A, Grigorenko EL, et al. Induced pluripotent stem cells: a new tool to confront the challenge of neuropsychiatric disorders. Neuropharmacology. 2011;60(7–8):1355–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol. 2012;9(9):520–8.

    CAS  PubMed  Google Scholar 

  127. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet. 2013;1(2):158–63.

    PubMed  Google Scholar 

  128. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1–3):1–23.

    PubMed  Google Scholar 

  129. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol. 2013;27(4):337–42.

    PubMed  PubMed Central  Google Scholar 

  130. Prasad KM, Eack SM, Keshavan MS, Yolken RH, Iyengar S, Nimgaonkar VL. Antiherpes virus-specific treatment and cognition in schizophrenia: A test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull. 2013;39(4):857–66.

    PubMed  Google Scholar 

  131. Phillips LJ, McGorry PD, Garner B, Thompson KN, Pantelis C, Wood SJ, et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry. 2006;40(9):725–41.

    PubMed  Google Scholar 

  132. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “Just the Facts”: what we know in 2008 part 1: overview. Schizophr Res. 2008;100(1–3):4–19.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, 75 Fenwood Road, Boston, MA, 02115, USA

    Jaya Padmanabhan

  2. Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA

    Matcheri S. Keshavan

Authors
  1. Jaya Padmanabhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matcheri S. Keshavan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaya Padmanabhan .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Rush University, Chicago, Illinois, USA

    Philip G. Janicak

  2. UCLA Semel Institute, Los Angeles, California, USA

    Stephen R. Marder

  3. College of Medicine, University of Florida, Gainesville, Florida, USA

    Rajiv Tandon

  4. Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, Illinois, USA

    Morris Goldman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Padmanabhan, J., Keshavan, M.S. (2014). Pathophysiology of Schizophrenia. In: Janicak, P., Marder, S., Tandon, R., Goldman, M. (eds) Schizophrenia. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0656-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0656-7_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0655-0

  • Online ISBN: 978-1-4939-0656-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation